Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit.San Francisco — An everolimus-eluting stent with a resorbable scaffold showed superior efficacy in a randomized multicenter trial when compared withThe stent was also noninferior to angioplasty in terms of safety.
Esprit BTK is a drug-eluting resorbable scaffold consisting of a temporary scaffold backbone of poly and a strut thickness of 99 μm. It is coated withLIFE-BTK enrolled patients aged 18 years or older with CLTI associated with ischemic rest pain or minor tissue loss and who had infrapopliteal artery stenosis or occlusion.
An independent committee adjudicated clinical events, and core laboratories with assessors blinded to trial group assignment adjudicated imaging results and wound assessments.Participants were about two thirds men, largely White, with about 15% of participants being Black/African American, and more than 90% of patients in each arm had. Lesion lengths were approximately 44 mm in each group with reference vessel diameters averaging 2.82-2.94 mm before intervention.
"If this technology is approved by FDA, it will provide a new option for our patients with very difficult-to-treat disease, which will provide them additional durability and fewer reinterventions," Varcoe concluded."And I think we all know deep down that's going to translate to improved clinical outcomes and few amputations."
He said that drug-eluting stents have demonstrated efficacy in this indication but that these studies have been limited to fairly discrete proximal disease.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: fox43 - 🏆 564. / 51 Read more »
Source: fox43 - 🏆 564. / 51 Read more »
Source: fox43 - 🏆 564. / 51 Read more »
Source: SciTechDaily1 - 🏆 84. / 68 Read more »
Source: CBS21NEWS - 🏆 304. / 63 Read more »
Source: soompi - 🏆 574. / 51 Read more »